CicloMed LLC is a developmental-stage pharmaceutical company with a collaborative team of experts in drug development and cancer treatment. The company is focused on developing a novel drug candidate called Ciclopirox Prodrug for potential treatment of bladder cancer. This paradigm-changing approach stems from a productive public-private partnership with The University of Kansas Cancer Center. The drug was licensed to CicloMed in 2015. The company's team is collaborating with experts across the country to develop this innovative drug for the treatment of muscle invasive and non-muscle invasive bladder cancer. With a stronghold in the Health Care and Pharmaceutical industries, CicloMed aims to disrupt the current landscape of bladder cancer treatment.
There is no investment information
No recent news or press coverage available for CicloMed LLC.